TickerFacts.

Stoke Therapeutics, Inc. (STOK): Capital Expenditures

Annual figures by period end, from SEC filings.

$670.0K
Year ended 2025-12-31
$2.69M
Trailing 12 months to 2026-06-30
-44.7%
3-year compound annual growth
-8.6%
5-year compound annual growth
$3.96M2018-12-31: $935.0K2019-12-31: $1.64M2020-12-31: $1.05M2021-12-31: $1.20M2022-12-31: $3.96M2023-12-31: $1.62M2024-12-31: $203.0K2025-12-31: $670.0K$670.0K
2018-12-31 Capital Expenditures (USD) 2025-12-31
Period endedCapital ExpendituresChange YoYSource filing
2025-12-31$670.0K+230.0%2026-03-16, From 2025-01-01
2024-12-31$203.0K-87.4%2026-03-16, From 2024-01-01
2023-12-31$1.62M-59.2%2025-03-18, From 2023-01-01
2022-12-31$3.96M+230.2%2024-03-25, From 2022-01-01
2021-12-31$1.20M+14.3%2023-03-06, From 2021-01-01
2020-12-31$1.05M-35.8%2022-03-10, From 2020-01-01
2019-12-31$1.64M+74.9%2021-03-09, From 2019-01-01
2018-12-31$935.0Kn/a2020-03-23, From 2018-01-01

Capital Expenditures at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCapital ExpendituresChange YoY
Stoke Therapeutics, Inc. (STOK)2025-12-31$670.0K+230.0%
Maravai Lifesciences Holdings, Inc. (MRVI)2025-12-31$13.15M-55.7%
Lifevantage Corp (LFVN)2026-06-30$3.57M+160.5%
Rhythm Pharmaceuticals, Inc. (RYTM)2025-12-31$953.0Kn/a
Cryoport, Inc. (CYRX)2025-12-31$16.44M-4.7%
Phathom Pharmaceuticals, Inc. (PHAT)2025-12-31$229.0K+69.6%
Syndax Pharmaceuticals Inc (SNDX)2025-12-31$187.0Kn/a
Liquidia Corp (LQDA)2025-12-31$4.34M-12.4%
Vanda Pharmaceuticals Inc. (VNDA)2025-12-31$998.0K+103.7%

Compare STOK, MRVI, LFVN, RYTM side by side · Screen every company in Pharmaceutical Preparations ↗